The TB Alliance Fast Track the Cure initiative launched a Request for proposals (RFP): Fast Track the Cure: Community engagement and awareness building for new drug-resistant TB (DR-TB) treatments.

CANBERRA (25 March 2024)—The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Alliance through its Product Development and Access Partnerships program. The funding will contribute toward the completion of the NC-009 Pan-Phase 2 clinical trial and also help establish and sustain the Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub in Manila, which will disseminate best practices to help speed the programmatic implementation of innovative, effective tuberculosis treatments, including the World Health Organization (WHO) recommended six-month, all-oral BPaL/M regimens for drug-resistant tuberculosis (DR-TB).

A combination of a new experimental compound, TBAJ-876, with pretomanid and linezolid, has the potential to become a 'universal TB regimen', shortening and improving treatment for both drug-sensitive and drug-resistant TB.

Results of LIFT-TB operational research on BPaL regimen for treating drug-resistant TB in Central and Southeast Asia.

Macleods becomes second pharmaceutical manufacturer to bring pretomanid supply to market and first since the World Health Organization issued updated DR-TB treatment guidelines.

ISLAMABAD and PRETORIA (9 November 2023)—The Association for Social Development (ASD) has registered 206 participants with drug-resistant tuberculosis (DR-TB) in Pakistan through a pilot program for treatment with new regimens recently recommended by the World Health Organization (WHO), known as BPaL/M – combinations of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin. ASD reported that out of 113 treatment outcomes declared, so far 105 (95%) have been successful—matching the success rates found elsewhere in the world with these new regimens and a drastic improvement over results with prior drug-resistant TB therapies. As an outcome of these positive results, Pakistan has updated its treatment guidelines for DR-TB to enable the use of these six-month, all-oral regimens.

PRETORIA (September 18, 2023)—Kyrgyzstan, Ukraine, and Uzbekistan – participants in the LIFT-TB project – have updated their National Tuberculosis (TB) Clinical Guidelines to endorse the all-oral, six-month BPaL/M (bedaquiline + pretomanid + linezolid ± moxifloxacin) regimen(s) as the national standard for treating most patients with drug-resistant tuberculosis (DR-TB).

NEW YORK (August 10, 2023)—Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medicine pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin). Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB. Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.

SEATTLE (February 20, 2023)—Results of TB Alliance’s SimpliciTB clinical trial were presented today at the 30th annual CROI 2023 conference. SimpliciTB was conducted to evaluate the BPaMZ regimen, consisting of bedaquiline (B), pretomanid (Pa), moxifloxacin (M), and pyrazinamide (Z). This combination previously showed high efficacy and treatment shortening potential in both preclinical evaluations and an early-stage clinical study in drug-resistant patients.

SEONGNAM-SI, South Korea and NEW YORK, US, February 3, 2023: Qurient Co. Ltd. (“Qurient”, KRX: 115180), a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs, announced today that they have entered into a license agreement to develop and commercialize telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis (TB) and other non-tuberculosis mycobacterium infections.